Search Results - "Arora, Anupa K"

Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition by Pontecorvo, Michael J, Devous, Sr, Michael D, Navitsky, Michael, Lu, Ming, Salloway, Stephen, Schaerf, Frederick W, Jennings, Danna, Arora, Anupa K, McGeehan, Anne, Lim, Nathaniel C, Xiong, Hui, Joshi, Abhinay D, Siderowf, Andrew, Mintun, Mark A

“…The advent of tau-targeted positron emission tomography tracers such as flortaucipir (18F-AV-1451, also known as 18F-T807) have made it possible to investigate…”
Get full text

Quantitation of PET signal as an adjunct to visual interpretation of florbetapir imaging by Pontecorvo, Michael J., Arora, Anupa K., Devine, Marybeth, Lu, Ming, Galante, Nick, Siderowf, Andrew, Devadanam, Catherine, Joshi, Abhinay D., Heun, Stephen L., Teske, Brian F., Truocchio, Stephen P., Krautkramer, Michael, Devous, Michael D., Mintun, Mark A.

“…Purpose This study examined the feasibility of using quantitation to augment interpretation of florbetapir PET amyloid imaging. Methods A total of 80 physician…”
Get full text

Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer’s disease pathology: a clinicopathological study by Pontecorvo, Michael J., Keene, C. Dirk, Beach, Thomas G., Montine, Thomas J., Arora, Anupa K., Devous, Michael D., Navitsky, Michael, Kennedy, Ian, Joshi, Abhinay D., Lu, Ming, Serrano, Geidy E., Sue, Lucia I., Intorcia, Anthony J., Rose, Shannon E., Wilson, Angela, Hellstern, Leanne, Coleman, Natalie, Flitter, Matthew, Aldea, Patricia, Fleisher, Adam S., Mintun, Mark A., Siderowf, Andrew

“…Background The objective of this study was to make a quantitative comparison of flortaucipir PET retention with pathological tau and β-amyloid across a range…”
Get full text

Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer's disease by Shcherbinin, Sergey, Morris, Amanda, Higgins, Ixavier A, Tunali, Ilke, Lu, Ming, Deveau, Carmen, Southekal, Sudeepti, Kotari, Vikas, Evans, Cynthia D, Arora, Anupa K, Collins, Emily C, Pontecorvo, Michael, Mintun, Mark A, Sims, John R

“…Alzheimer's disease (AD) is characterized by the presence of both amyloid and tau pathology. In vivo diagnosis can be made with amyloid and tau positron…”
Get full text

A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia by Pontecorvo, Michael J, Devous, Michael D, Kennedy, Ian, Navitsky, Michael, Lu, Ming, Galante, Nicholas, Salloway, Stephen, Doraiswamy, P Murali, Southekal, Sudeepti, Arora, Anupa K, McGeehan, Anne, Lim, Nathaniel C, Xiong, Hui, Truocchio, Stephen P, Joshi, Abhinay D, Shcherbinin, Sergey, Teske, Brian, Fleisher, Adam S, Mintun, Mark A

“…The advent of tau-targeted PET tracers such as flortaucipir (18F) (flortaucipir, also known as 18F-AV-1451 or 18F-T807) have made it possible to investigate…”
Get full text

Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes by Fleisher, Adam S, Pontecorvo, Michael J, Devous, Sr, Michael D, Lu, Ming, Arora, Anupa K, Truocchio, Stephen P, Aldea, Patricia, Flitter, Matthew, Locascio, Tricia, Devine, Marybeth, Siderowf, Andrew, Beach, Thomas G, Montine, Thomas J, Serrano, Geidy E, Curtis, Craig, Perrin, Allison, Salloway, Stephen, Daniel, Misty, Wellman, Charles, Joshi, Abhinay D, Irwin, David J, Lowe, Val J, Seeley, William W, Ikonomovic, Milos D, Masdeu, Joseph C, Kennedy, Ian, Harris, Thomas, Navitsky, Michael, Southekal, Sudeepti, Mintun, Mark A

“…Positron emission tomography (PET) may increase the diagnostic accuracy and confirm the underlying neuropathologic changes of Alzheimer disease (AD). To…”
Get more information

Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease: Results From 2 Phase III Clinical Trials by Lu, Ming, Pontecorvo, Michael J, Devous, Sr, Michael D, Arora, Anupa K, Galante, Nicholas, McGeehan, Anne, Devadanam, Catherine, Salloway, Stephen P, Doraiswamy, P Murali, Curtis, Craig, Truocchio, Stephen P, Flitter, Matthew, Locascio, Tricia, Devine, Marybeth, Zimmer, Jennifer A, Fleisher, Adam S, Mintun, Mark A

“…Flortaucipir positron emission tomography (PET) scans, rated with a novel, US Food and Drug Administration-approved, clinically applicable visual…”
Get more information

Potential Impact of Amyloid Imaging on Diagnosis and Intended Management in Patients With Progressive Cognitive Decline by GRUNDMAN, Michael, PONTECORVO, Michael J, AGBULOS, Abigail, FLITTER, Matthew L, KRAUTKRAMER, Michael J, SARSOUR, Khaled, SKOVRONSKY, Daniel M, MINTUN, Mark A, SALLOWAY, Stephen P, MURALI DORAISWAMY, P, FLEISHER, Adam S, SADOWSKY, Carl H, NAIR, Anil K, SIDEROWF, Andrew, MING LU, ARORA, Anupa K

“…Florbetapir F18 has been approved by the Food and Drug Administration for in vivo assessment of amyloid pathology in patients undergoing evaluation for…”
Get full text

Clinical and cortical decline in the aphasic variant of Alzheimer's disease by Rogalski, Emily Joy, Sridhar, Jaiashre, Martersteck, Adam, Rader, Benjamin, Cobia, Derin, Arora, Anupa K., Fought, Angela J., Bigio, Eileen H., Weintraub, Sandra, Mesulam, Marek-Marsel, Rademaker, Alfred

“…Primary progressive aphasia (PPA) displays variable progression trajectories that require further elucidation. Longitudinal quantitation of atrophy and…”
Get full text

Effect of Amyloid Imaging on the Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use Criteria by Grundman, Michael, Johnson, Keith A, Lu, Ming, Siderowf, Andrew, Dell'Agnello, Grazia, Arora, Anupa K, Skovronsky, Daniel M, Mintun, Mark A, Pontecorvo, Michael J

“…Published appropriate use criteria (AUC) describe patients for whom amyloid positron emission tomography (PET) might be most useful. This study compared the…”
Get more information